Eli Lilly agreed to acquire Adverum to advance ixoberogene soroparvovec (ixo‑vec), a one‑time AAV‑based gene therapy in Phase III for wet age‑related macular degeneration (wAMD). Lilly said it pursued the full company to ensure continuity of the pivotal trial and retain Adverum’s development team to accelerate the program. Adverum had disclosed cash constraints and a limited runway; Lilly’s acquisition provides funding and development resources to complete the ongoing registrational study. Ixo‑vec is designed to deliver sustained intraocular aflibercept expression from a single intravitreal dose, potentially replacing chronic intravitreal injections if approved. The deal expands Lilly’s sensory therapeutics footprint into ophthalmology and reflects Big Pharma interest in durable, single‑administration gene therapies. Regulators will review trial data and durability and safety signals typical for AAV vectors as the programs proceed.